Clinical outcomes during and beyond different COVID-19 critical illness variant periods compared with other lower respiratory tract infections.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
06 11 2023
Historique:
received: 29 08 2023
accepted: 02 11 2023
medline: 8 11 2023
pubmed: 7 11 2023
entrez: 7 11 2023
Statut: epublish

Résumé

It is yet to be better understood how outcomes during and after the critical illness potentially differ between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants from other lower respiratory tract infections (LRTIs). We aimed to compare outcomes in adults admitted to an intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) during the Wild-type, Alpha, Delta, and Omicron periods with individuals admitted with other LRTI. Population-based cohort study in Stockholm, Sweden, using health registries with high coverage, including ICU-admitted adults from 1 January 2016 to 15 September 2022. Outcomes were in-hospital mortality, 180-day post-discharge mortality, 180-day hospital readmission, 180-day days alive and at home (DAAH), and incident diagnoses registered during follow-up. The number of ICU admitted individuals were 1421 Wild-type, 551 Alpha, 190 Delta, 223 Omicron, and 2380 LRTI. In-hospital mortality ranged from 28% (n = 665) in the LRTI cohort to 35% (n = 77) in the Delta cohort. The adjusted cause-specific hazard ratio (CSHR) compared with the LRTI cohort was 1.33 (95% confidence interval [CI] 1.16-1.53) in the Wild-type cohort, 1.53 (1.28-1.82) in the Alpha cohort, 1.70 (1.30-2.24) in the Delta cohort, and 1.59 (1.24-2.02) in the Omicron cohort. Among patients discharged alive from their COVID-19 hospitalization, the post-discharge mortality rates were lower (1-3%) compared with the LRTI cohort (9%), and the risk of hospital readmission was lower (CSHRs ranging from 0.42 to 0.68). Moreover, all COVID-19 cohorts had compared with the LRTI cohort more DAAH after compared with before the critical illness. Overall, COVID-19 critical was associated with an increased hazard of in-hospital mortality, but among those discharged alive from the hospital, less severe long-term outcomes were observed compared with other LRTIs.

Sections du résumé

BACKGROUND
It is yet to be better understood how outcomes during and after the critical illness potentially differ between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants from other lower respiratory tract infections (LRTIs). We aimed to compare outcomes in adults admitted to an intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) during the Wild-type, Alpha, Delta, and Omicron periods with individuals admitted with other LRTI.
METHODS
Population-based cohort study in Stockholm, Sweden, using health registries with high coverage, including ICU-admitted adults from 1 January 2016 to 15 September 2022. Outcomes were in-hospital mortality, 180-day post-discharge mortality, 180-day hospital readmission, 180-day days alive and at home (DAAH), and incident diagnoses registered during follow-up.
RESULTS
The number of ICU admitted individuals were 1421 Wild-type, 551 Alpha, 190 Delta, 223 Omicron, and 2380 LRTI. In-hospital mortality ranged from 28% (n = 665) in the LRTI cohort to 35% (n = 77) in the Delta cohort. The adjusted cause-specific hazard ratio (CSHR) compared with the LRTI cohort was 1.33 (95% confidence interval [CI] 1.16-1.53) in the Wild-type cohort, 1.53 (1.28-1.82) in the Alpha cohort, 1.70 (1.30-2.24) in the Delta cohort, and 1.59 (1.24-2.02) in the Omicron cohort. Among patients discharged alive from their COVID-19 hospitalization, the post-discharge mortality rates were lower (1-3%) compared with the LRTI cohort (9%), and the risk of hospital readmission was lower (CSHRs ranging from 0.42 to 0.68). Moreover, all COVID-19 cohorts had compared with the LRTI cohort more DAAH after compared with before the critical illness.
CONCLUSION
Overall, COVID-19 critical was associated with an increased hazard of in-hospital mortality, but among those discharged alive from the hospital, less severe long-term outcomes were observed compared with other LRTIs.

Identifiants

pubmed: 37932793
doi: 10.1186/s13054-023-04722-0
pii: 10.1186/s13054-023-04722-0
pmc: PMC10629059
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

427

Subventions

Organisme : HORIZON EUROPE European Research Council
ID : 101046016
Organisme : Vetenskapsrådet
ID : 2021-04809

Informations de copyright

© 2023. The Author(s).

Références

Intensive Care Med. 2012 Oct;38(10):1647-53
pubmed: 22777516
J Infect. 2023 Aug;87(2):120-127
pubmed: 37201858
Clin Microbiol Infect. 2023 Jul;29(7):835-844
pubmed: 36934872
Intensive Care Med. 2023 Jun;49(6):697-699
pubmed: 37067557
Intensive Care Med. 2022 Mar;48(3):366-368
pubmed: 35041016
Crit Care. 2021 Feb 25;25(1):86
pubmed: 33632273
Am J Respir Crit Care Med. 2022 May 15;205(10):1159-1168
pubmed: 35258437
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
Nat Commun. 2022 Oct 12;13(1):6025
pubmed: 36224216
Nat Commun. 2020 Oct 9;11(1):5097
pubmed: 33037218
BMJ. 2022 Jan 17;376:e066809
pubmed: 35039315
Crit Care Med. 2022 Feb 1;50(2):245-255
pubmed: 34259667
Am J Respir Crit Care Med. 2022 Aug 1;206(3):349-363
pubmed: 35536284
Lancet Reg Health Eur. 2021 May;4:100054
pubmed: 33997829
J Intern Med. 2023 Feb;293(2):246-258
pubmed: 36478477
Euro Surveill. 2006 May;11(5):15-16
pubmed: 29208143
Am J Respir Crit Care Med. 2021 Oct 15;204(8):902-909
pubmed: 34319848
JAMA Netw Open. 2023 Mar 1;6(3):e233265
pubmed: 36929399
J Clin Epidemiol. 2013 Jun;66(6):648-53
pubmed: 23415868

Auteurs

Pontus Hedberg (P)

Department of Medicine, Huddinge, Karolinska Institutet, H7 Medicin, Huddinge, H7 Infektion och Hud Sönnerborg, 171 77, Stockholm, Sweden. Pontus.hedberg@ki.se.

Nicholas Baltzer (N)

Division of Infectious Diseases, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Fredrik Granath (F)

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Michael Fored (M)

Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Johan Mårtensson (J)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.

Pontus Nauclér (P)

Division of Infectious Diseases, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH